clozapine
Trade name: clozaril
Approved
Sep 26, 1989
Clozapine was discovered in 1958 by an anesthetist and now it is used for the treatment of schizophrenia. Although the exact mechanism of its action is unknown, the effect of clozapine on schizophrenia is associated with inhibition of dopamine D2 and serotonin 2A receptors. — NCATS
Clinical trial activity
76 trials · 87 clinical orgs · 16 marketing orgs
Earliest trial started Oct 1, 1993 (NCT00004826)
Timeline
1980s
- Sep 26, 1989
Heritage Pharma — Earliest FDA Approval
- Sep 26, 1989
Heritage Pharma — NDA Organization
- Sep 26, 1989
Heritage Pharma — NDA Secondary Org
1990s
2000s
- Jan 1, 2000
Earliest Phase 1 Sponsor(trial)
- Jan 1, 2001
- Nov 15, 2002
Sun Pharmaceuticals — Marketing Organization
- Feb 10, 2004
Jazz Pharmaceuticals — NDA Secondary Org
- Apr 26, 2005
Par Pharmaceuticals — Marketing Organization
2010s
- Feb 6, 2013
Tasman Pharma — NDA Secondary Org
- Feb 6, 2013
Douglas Pharmaceuticals — Marketing Organization
- Sep 17, 2015
Mayne Pharma — Marketing Organization
- Sep 17, 2015
Dr. Reddy's Laboratories — Marketing Organization
- Nov 25, 2015
Accord Research — Marketing Organization
- Nov 25, 2015
Barr Laboratories — Marketing Organization
- Nov 29, 2016
Aurobindo Pharma — Marketing Organization
- Dec 6, 2017
Zydus Discovery DMCC — Marketing Organization
Indications
Approved for
Studied for
- Alcoholism · Phase 4
- Anxiety Disorders · Phase 3
- Bipolar Disorder · Phase 4
- Dementia · Phase 3
- Depression · Phase 3
- Developmental Disabilities · Phase 3
- Diagnosis, Dual (Psychiatry) · Phase 4
- Healthy Volunteers · Phase 1
- Intellectual Disability · Phase 3
- Intractable Pain · Early Phase 1
- Liver Diseases · Phase 1
- Major Depressive Disorder · Phase 4
- Marijuana Abuse · Phase 4
- Metabolic Syndrome · Phase 4
- Panic Disorder · Phase 4
- Pharmacology · Phase 1
- Psychophysiologic Disorders · Phase 3
- Psychotic Disorders · Phase 4
- Renal Insufficiency · Phase 1
- Schizophrenia, Childhood · Phase 4
- Schizophrenia, Treatment-Resistant · Phase 4
- Substance-Related Disorders · Phase 4
- Therapeutics · Phase 4
Mechanism of action
- Serotonin 2a (5-HT2a) receptorANTAGONIST
HTR2A antagonist
- Dopamine D2 receptorANTAGONIST
DRD2 antagonist
Approval history
- approvedPriority reviewSep 26, 1989
Chemistry & pharmacology
SMILES
CN1CCN(CC1)C2=NC3=CC(Cl)=CC=C3NC4=CC=CC=C24- Mol. weight
- 326.823 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaClozapine ↗
- NCATSJ60AR2IKIC ↗
- ChEMBLCHEMBL42 ↗
Also known as
- asaleptin
- azaleptine
- clozapin
- clozapin
- clozapin
- clozapina
- clozapina
- clozapine
- clozapine
- clozapine
- clozapine
- clozapine
- clozapine
- clozapine
- clozapine
- clozapine
- clozapine
- clozapine
- clozapine
- clozapinum
- clozapinum
- clozaril
- clozaril
- clozaril
- clozaril
- clozaril
- fazaclo
- fazaclo
- fazaclo
- fazaclo odt
- fazaclo odt
- hf-1854
- hf-1854
- klozapol
- leponex
- lu af35700
- zaponex
- zaponex
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06969755 | Phase 4 | Jul 30, 2025 | National Institute of Mental Health (NIMH), Northwell Health |
| NCT06596681 | Early Phase 1 (Phase 1) | Sep 12, 2024 | Capital Medical University |
| NCT05958875 | Phase 4 | Nov 1, 2023 | University of Munster, Utrecht University |
| NCT05741502 | Phase 4 | Aug 16, 2023 | Ohio State University |
| NCT05603104 | Phase 4 | Aug 1, 2023 | University of Munster, Utrecht University |
| NCT06906224 | Early Phase 1 (Phase 1) | May 1, 2022 | Bengbu Medical College |
| NCT05208190 | Phase 4 | Mar 17, 2022 | Columbia University, National Institute of Mental Health (NIMH) |
| NCT05316883 | Phase 4 | Feb 28, 2021 | Mental health Service, Glostrup, Mental Health Services in the Capital Region, Denmark |
| NCT07262736 | Phase 1 | Feb 6, 2021 | Univerisiti Sains Malaysia |
| NCT04849026 | Phase 1 | Jan 15, 2021 | Naju National Hospital, Whanin Pharmaceutical Company |
| NCT04528095 | Phase 3 | Dec 31, 2020 | Jiao Tong University |
| NCT04580134 | Phase 4 | Dec 31, 2020 | Harvard University, National Institute of Mental Health (NIMH), The University of Texas, Dallas, University of Chicago, University of Connecticut, University of Georgia |
| NCT04529226 | Phase 2 | Sep 30, 2020 | Andalusian Health Service, Fundación Pública Andaluza |
| NCT04240496 | N/A | Oct 17, 2019 | University of Monastir |
| NCT03857581 | Phase 4 | Jul 31, 2019 | Augusta University |
| NCT03807882 | Phase 4 | Feb 1, 2019 | All India Institute of Medical Sciences |
| NCT03772951 | N/A | Jan 10, 2019 | Jiao Tong University |
| NCT03670082 | Phase 1 | Sep 5, 2018 | Lundbeck |
| NCT03652974 | N/A | Aug 1, 2018 | Jiao Tong University |
| NCT03394482 | Phase 1 | Jan 3, 2018 | Lundbeck |
Organizations
Research & Development (87)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Mental Health (NIMH) | Government | 14 | 5 | 4 | 1994 |
| Lundbeck | For profit | 12 | 12 | 3 | 2013 |
| Dartmouth University | Academic/Hospital | 7 | 4 | 2 | 1994 |
| Harvard University | Academic/Hospital | 6 | 4 | 2 | 1994 |
| Jiao Tong University | Academic/Hospital | 5 | 4 | 3 | 2005 |
| Novartis | For profit | 5 | 2 | 3 | 1994 |
| National Institutes of Health (NIH) | Government | 3 | 1 | 2 | 1997 |
| Northwell Health | Academic/Hospital | 3 | 3 | 2 | 2000 |
| University of Toronto | Academic/Hospital | 3 | 3 | 2 | 1999 |
| Utrecht University | Academic/Hospital | 3 | 2 | 1 | 2011 |
| Ben Gurion University | Academic/Hospital | 2 | 1 | 2 | 2005 |
| Capital Medical University | Academic/Hospital | 2 | 1 | 2 | 2005 |
| Naju National Hospital | Academic/Hospital | 2 | 0 | 1 | 2012 |
| New York University | Academic/Hospital | 2 | 1 | 2 | 1999 |
| Seoul National University | Academic/Hospital | 2 | 1 | 2 | 2011 |
| Taipei Medical University | Academic/Hospital | 2 | 2 | 1 | 2008 |
| Technion University | Academic/Hospital | 2 | 2 | 2 | 2011 |
| University of Massachusetts | Academic/Hospital | 2 | 1 | 1 | 2009 |
| University of Munster | Academic/Hospital | 2 | 0 | 1 | 2023 |
| University of South Carolina | Academic/Hospital | 2 | 0 | 1 | 2000 |
Marketing (21)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Accord Research | For profit | MKTG | Nov 25, 2015 |
| Aurobindo Pharma | For profit | SYN | Nov 29, 2016 |
| Aurobindo Pharma | For profit | MKTG | Nov 29, 2016 |
| Barr Laboratories | For profit | MKTG | Nov 25, 2015 |
| Douglas Pharmaceuticals | For profit | MKTG | Feb 6, 2013 |
| Dr. Reddy's Laboratories | For profit | MKTG | Sep 17, 2015 |
| Heritage Pharma | For profit | NDA | Sep 26, 1989 |
| Heritage Pharma | For profit | NDA2 | Sep 26, 1989 |
| Jazz Pharmaceuticals | For profit | NDA2 | Feb 10, 2004 |
| Jazz Pharmaceuticals | For profit | SYN | Feb 10, 2004 |
| Mayne Pharma | For profit | MKTG | Sep 17, 2015 |
| Mylan | For profit | MKTG | May 27, 1999 |
| Mylan | For profit | SYN | Sep 15, 2015 |
| Novartis | For profit | MKTG | Aug 30, 1996 |
| Par Pharmaceuticals | For profit | MKTG | Apr 26, 2005 |
| Sandoz | For profit | MKTG | Aug 30, 1996 |
| Sun Pharmaceuticals | For profit | MKTG | Nov 15, 2002 |
| Tasman Pharma | For profit | NDA2 | Feb 6, 2013 |
| Teva | For profit | MKTG | Nov 26, 1997 |
| Teva | For profit | SYN | Nov 25, 2015 |
| Zydus Discovery DMCC | For profit | MKTG | Dec 6, 2017 |